Related Experiment Video

Updated: Feb 28, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

14.0K

A Case of Locally Advanced Castration-resistant Prostate Cancer With Remarkable Response to Nivolumab

Alina Basnet1, Gaurav Khullar2, Rohin Mehta2

  • 1Department of Hematology/Oncology, SUNY Upstate Medical University, Syracuse, NY.

Clinical Genitourinary Cancer
|June 20, 2017
PubMed
Abstract

No abstract available in PubMed .

Keywords:
Androgen deprivation therapyCastrate resistantImmunotherapyNivolumabProstate cancer

More Related Videos

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients
12:13

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

7.3K
A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

938

Related Experiment Videos

Last Updated: Feb 28, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

14.0K
Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients
12:13

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

7.3K
A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

938

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.8K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K

Articles linked to this work by shared authors, journal, and citation graph.

Identification of a novel class of early exon ALK rearrangements across two pan-tumor sequencing databases.

Cancer genetics·2026

Homologous recombination deficiency and genomic alterations in advanced prostate cancer: insights for precision therapy.

The oncologist·2026

Fanconi anemia complementation group C gene (FANCC) association with hereditary and sporadic renal tumors.

The oncologist·2026

Staging Invasive Lobular Carcinoma: A Prospective Study on the Efficacy of 18F-Fluoroestradiol (FES)-PET/CT.

Clinical breast cancer·2025

Predicting the Tumor Microenvironment Composition and Immunotherapy Response in Non-Small Cell Lung Cancer from Digital Histopathology Images.

medRxiv : the preprint server for health sciences·2025

Real-world deployment of a fine-tuned pathology foundation model for lung cancer biomarker detection.

Nature medicine·2025

Time to Partial Nephrectomy Versus Cancer-Specific Mortality in 2 to 4 cm Renal Cell Carcinoma.

Clinical genitourinary cancer·2026

Dosing, Safety, and Pharmacokinetics of Combination Therapy With Darolutamide, Androgen Deprivation Therapy, and Docetaxel for Metastatic Hormone-Sensitive Prostate Cancer in the ARASENS Study.

Clinical genitourinary cancer·2026

Functional Outcomes of High-Risk Prostate Cancer Patients Treated With Neoadjuvant Androgen Deprivation Therapy (nADT) Prior to Radical Prostatectomy.

Clinical genitourinary cancer·2026

Log Odds of Positive Lymph Nodes as a Novel Prognostic Predictor for Bladder Cancer: A Systematic Review and Meta-Analysis.

Clinical genitourinary cancer·2026

A Risk-Adapted Framework for Adjuvant Pembrolizumab Plus Belzutifan in Resected Clear Cell Renal Cell Carcinoma.

Clinical genitourinary cancer·2026

Prolonged Surgical Waiting Time for Radical Nephroureterectomy Is Associated With Worse Survival Outcomes in Patients With Upper Tract Urothelial Carcinoma.

Clinical genitourinary cancer·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us